Usefulness of Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux.

Randomized, prospective, multicenter study in order to assess the usefulness of antimicrobial prophylaxis in children with isolated vesico-ureteral reflux (grade III or less)...

Date First Received: September 12, 2005

Last Updated: June 30, 2008

Verified by: Nantes University Hospital, June 2008

Clinical Trial Phase: N/A | Start Date: April 2001

Overall Status: Completed

Estimated Enrollment: 232

Brief Summary

Official Title: “Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux. A Randomised Prospective Study of Continuous Low Dose of Trimethoprim-Sulfamethoxazole Versus Surveillance.”

Condition Keyword(s):

Randomized, prospective, multicenter study in order to assess the usefulness of antimicrobial prophylaxis in children with isolated vesico-ureteral reflux (grade III or less).

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment

Study Primary Completion Date: July 2006

Detailed Clinical Trial Description

A voiding cystourethrogram was performed for each child less than 3 years old with a first urinary tract infection. In case of vesico-ureteral reflux, a randomization was done between continuous antimicrobial prophylaxis with low dose of trimethoprim-sulfamethoxazole and no antibioprophylaxis. Duration of follow up was 18 months.

Intervention(s) in this Clinical Trial

  • Procedure: Antimicrobial prophylaxis

Outcome Measures for this Clinical Trial

Primary Measures

  • End point : recurrence of urinary tract infection during the study period (0 รจ 18 months)

Secondary Measures

  • 1) Type of urinary tract infection (pyelonephritis or cystitis)
  • 2) Evaluation of the quality of life with a validated questionnaire done at 9 months

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Children less than 3 years old
  • First proved urinary tract infectionIsolated vesico-ureteral reflux
  • Parents have been fully informed and have given written informed consent to participate in the study

Exclusion Criteria:

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: 3 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Nantes University Hospital

Overall Clinical Trial Officials and Contacts

Claude GUYOT, MD Principal Investigator Nantes University Hospital  

Additional Information

Information obtained from ClinicalTrials.gov on September 08, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00200616

Study ID Number: BRD/00/10-O

ClinicalTrials.gov Identifier: NCT00200616

Health Authority: France: Ministry of Health

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.